Results 21 to 30 of about 33,995 (211)

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM) : study protocol for a randomized controlled trial [PDF]

open access: yes, 2014
Background In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated ...
Squire, Stephen Bertel   +25 more
core   +1 more source

Fluoroquinolone Persistence in Escherichia coli Requires DNA Repair despite Differing between Starving Populations

open access: yesMicroorganisms, 2022
When faced with nutritional deprivation, bacteria undergo a range of metabolic, regulatory, and biosynthetic changes. Those adjustments, which can be specific or independent of the missing nutrient, often alter bacterial tolerance to antibiotics.
Annabel S. Lemma   +2 more
doaj   +1 more source

Emergence and spread of moxifloxacin-resistant Clostridium difficile ribotype 231 in Sweden between 2006 and 2015

open access: yesNew Microbes and New Infections, 2016
An aggregation of moxifloxacin-resistant Clostridium difficile ribotype 231 (RT231) isolates was first identified in the county of Stockholm in 2008, and by the end of 2015 isolates of RT231 had spread to 13 of 21 Swedish counties.
H. Harvala   +3 more
doaj   +1 more source

Two nitazoxanide-based quadruple regimens for eradication of Helicobacter pylori infection: a single-center randomized controlled trial

open access: yesAl-Azhar Assiut Medical Journal, 2022
Background and aim Eradication of Helicobacter pylori becomes an ongoing challenge worldwide because eradication rates of H. pylori are declining to less than 60% in some countries.
Amro M Hassan   +3 more
doaj   +1 more source

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

open access: yesBMC Anesthesiology, 2017
Background We tested the hypothesis that moxifloxacin monotherapy is equally effective and safe as a betalactam antibiotic based combination therapy in patients with acute respiratory distress syndrome (ARDS) evoked by severe community acquired pneumonia
Tim Rahmel   +5 more
doaj   +1 more source

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

open access: yes, 2015
Supported by the Global Alliance for TB Drug Development with support from the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership, U.S. Agency for International Development, U.K.
for the REMoxTB Consortium   +9 more
core   +1 more source

Time to reconsider moxifloxacin anti-anaerobic activity?

open access: yes, 2022
Large data on moxifloxacin activity on anaerobes are old. Moxifloxacin is often used for empiric therapy therefore the knowledge of current epidemiologic data is fundamental.
Richard Aschbacher   +13 more
core   +1 more source

Moxifloxacin promotes two-photon microscopic imaging for discriminating different stages of DSS-induced colitis on mice

open access: yesPhotodiagnosis and Photodynamic Therapy
Background: Accurate diagnosis of patients with ulcerative colitis (UC) can reduce their risk of developing colorectal cancer. This study intended to explore whether moxifloxacin, an agent with fluorescence potential, could promote two-photon microscopy (
Yingtong Chen   +11 more
doaj   +1 more source

Case Report: Drug-induced pneumonia caused by moxifloxacin and a literature review

open access: yesFrontiers in Medicine
Drug-induced pneumonia is a rare and potentially life-threatening adverse drug reaction. Moxifloxacin is a fluoroquinolone antibiotic with broad-spectrum antimicrobial activity.
Zhan Gao   +6 more
doaj   +1 more source

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections

open access: yes, 2008
Darlene MillerAbrams Ocular Microbiology Laboratory, Bascom Palmer Eye Institute, Anne Bates Leach Eye Hospital, Miller School of Medicine-University of Miami, FL, USAAbstract: Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox®) is the
Darlene Miller, Miller, Darlene
core   +1 more source

Home - About - Disclaimer - Privacy